Archive for February, 2014

(CLIR) Announces $6,500,000 Registered Direct Offering

SEATTLE, Feb. 28, 2014  — ClearSign Combustion Corporation (Nasdaq: CLIR), a Washington corporation, today announced that it has entered into subscription agreements with certain institutional investors to sell approximately $6.5 million of its common stock in a registered direct offering.

Under the terms of the subscription agreements, the Company will issue an aggregate of 812,500 shares of common stock at a price of $8.00 per share. The closing of the funding is expected to take place on or about March 5, 2014, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from this offering for research and development, protection of intellectual property, business development and marketing, and for working capital and general corporate purposes.

Brean Capital LLC acted as the sole placement agent in connection with the transaction.

A registration statement relating to the shares described above was previously filed with and has become effective by rule of the Securities and Exchange Commission (SEC). A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and related prospectus, when available, may be obtained from Brean Capital, LLC, 1345 Avenue of the Americas, 29th Floor, New York 10105, or by telephone at 212-702-6500 or by e-mail at syndicate@breancapital.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ClearSign Combustion Corporation

ClearSign Combustion Corporation designs and develops technologies that aim to improve key performance characteristics of combustion systems including energy efficiency, emissions control, fuel flexibility and overall cost effectiveness. Our Duplex™ Burner Architecture and Electrodynamic Combustion Control™ (ECC™) platform technologies improve control of flame shape and heat transfer and optimize the complex chemical reactions that occur during combustion in order to minimize harmful emissions. For more information about the Company, please visit www.clearsign.com

Cautionary note on forward-looking statements

This press release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events that are based on management’s belief, as well as assumptions made by, and information currently available to, management. While we believe that our expectations are based upon reasonable assumptions, there can be no assurances that our goals and strategy will be realized. Numerous factors, including risks and uncertainties, may affect our actual results and may cause results to differ materially from those expressed in forward-looking statements made by us or on our behalf. Some of these factors include the acceptance of existing and future products, the impact of competitive products and pricing, general business and economic conditions, and other factors detailed in our Quarterly Report on Form 10-Q and other periodic reports filed with the SEC. We specifically disclaim any obligation to update or revise any forward-looking statement whether as a result of new information, future developments or otherwise.

Friday, February 28th, 2014 Uncategorized Comments Off on (CLIR) Announces $6,500,000 Registered Direct Offering

(TTHI) and Perrigo Modify Development and Commercialization Rights of ELND005 Program

  • All development and commercialization rights of ELND005 drug candidate have been transferred to an Irish-domiciled company (“Irish Subsidiary”)
  • Transition has acquired 100% of the common shares of Irish Subsidiary
  • Irish Subsidiary will be responsible for the future development and commercialization of ELND005 for all disease indications
  • Affiliates of Perrigo Company plc (“Perrigo”) will invest US$15 million and receive newly issued Transition common shares representing a 7% ownership stake in Transition
  • Perrigo will be eligible to receive milestone payments and royalties from the approval and sale of ELND005 products

TORONTO, Feb. 28, 2014  – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI, TSX: TTH) announced the acquisition of an Irish domiciled company (“Irish Subsidiary”), the holder of all the development and commercialization rights of neuropsychiatric drug candidate, ELND005.    The Company also announced a US$15 million investment by Perrigo to acquire approximately 7% of Transition’s common shares.  ELND005 is an oral drug candidate that is being evaluated in three studies: a Phase 2 study for Agitation and Aggression in Alzheimer’s Disease, a Phase 2 study for Bipolar Disorder and a Phase 2A study in Down Syndrome.

After a series of transactions, Perrigo has transferred all of its ELND005 rights and assets to Irish Subsidiary.  Transition has acquired Irish Subsidiary, which is now a 100% wholly-owned, subsidiary of Transition.  In parallel with this acquisition, Perrigo has invested US$15 million and will receive 2,255,640 Transition common shares representing approximately a 7% ownership stake in Transition.   Perrigo will also be eligible to receive up to US$40 million in approval and commercial milestone payments and a 6.5% royalty on net sales of ELND005 products and sublicense fees received.   Going forward, Irish Subsidiary will be responsible for all future development and commercialization activities of the ELND005 drug candidate.

“ELND005 is a unique drug candidate that has been shown to have an acceptable safety profile in six clinical studies and reduced the emergence of multiple neuropsychiatric effects including agitation, aggression, depression and anxiety in a Phase 2 clinical study. By acquiring the ELND005 rights, Transition has the opportunity to complete the two current large Phase 2 studies underway in Agitation and Aggression in Alzheimer’s Disease, and mood changes in Bipolar Disorder. This drug candidate acts through a distinct mechanism of action by reducing brain myo-inositol levels associated with mood/behavioral changes. We believe this approach provides a unique opportunity to achieve therapeutic benefit for patients with neuropsychiatric symptoms.   We are very pleased to work with Perrigo and look forward to completing the current late-stage trials of ELND005”, said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.

About ELND005

ELND005 is an orally bioavailable small molecule that is being investigated for multiple neuropsychiatric indications on the basis of its proposed dual mechanism of action, which includes β-amyloid anti-aggregation and regulation of brain myo-inositol levels. An extensive clinical program of Phase 1 and Phase 2 studies has been completed with ELND005 to support clinical development, including the published Phase 2 study ELND005-AD201 in AD. ELND005 is also being studied as a potential treatment of agitation and aggression in Alzheimer’s disease (Study ELND005-AG201), as a maintenance therapy of Bipolar Disorder Type I (Study ELND005-BPD201) and as a therapy for those with Down syndrome (Study ELND005-DS-201).

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition’s lead CNS drug candidate is ELND005 for the treatment of Alzheimer’s disease and bipolar disorder.  Transition’s lead metabolic drug candidate is TT-401 for the treatment of type 2 diabetes and accompanying obesity. Transition’s shares are listed on the NASDAQ under the symbol “TTHI” and the Toronto Stock Exchange under the symbol “TTH”. For additional information about Transition, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials and potential efficacy of its products. These statements are based upon the current expectations and beliefs of Transition’s management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition’s control and the risk factors and other cautionary statements discussed in Transition’s quarterly and annual filings with the Canadian commissions.

SOURCE Transition Therapeutics Inc.

For further information on Transition, visit www.transitiontherapeutics.com or contact:
Dr. Tony Cruz
Chief Executive Officer
Transition Therapeutics Inc.
Phone: 416-260-7770, x.223
tcruz@transitiontherapeutics.com

Friday, February 28th, 2014 Uncategorized Comments Off on (TTHI) and Perrigo Modify Development and Commercialization Rights of ELND005 Program

(RVBD) Board of Directors Rejects Unsolicited Proposal from Elliott

Riverbed Technology (NASDAQ:RVBD), the leader in application performance infrastructure, today announced that its Board of Directors, after consideration with its independent legal and financial advisors, has unanimously determined not to pursue the unsolicited proposal from Elliott Management Corporation to acquire all of the outstanding shares of Riverbed common stock for $21.00 per share, as it believes the proposal undervalues the Company and is not in the best interests of shareholders.

As previously stated, the Board will carefully review any credible offer to acquire the Company that it receives. Any such offer must deliver value to our shareholders in excess of what we believe will be created as we execute on our growth plans. The Board remains focused on delivering value to all Riverbed shareholders.

Goldman, Sachs & Co. is serving as financial advisor to Riverbed and Wilson Sonsini Goodrich & Rosati is serving as legal advisor.

Forward-Looking Statements

This press release contains forward-looking statements, including those in respect of our growth strategy. These forward-looking statements involve risks and uncertainties. These forward-looking statements also involve assumptions that, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties that could cause our results to differ materially from those expressed or implied by such forward-looking statements include our ability to react to trends and challenges in our business and the markets in which we operate; our ability to anticipate market needs or develop new or enhanced products to meet those needs; the adoption rate of our products; our ability to establish and maintain successful relationships with our distribution partners; our ability to compete in our industry; fluctuations in demand, sales cycles and prices for our products and services; shortages or price fluctuations in our supply chain; our ability to protect our intellectual property rights; general political, economic and market conditions and events; and other risks and uncertainties described more fully in our documents filed with or furnished to the Securities and Exchange Commission. More information about these and other risks that may impact Riverbed’s business are set forth in our Form 10-K filed with the SEC for the period ended December 31, 2013, and our subsequent quarterly reports filed with the SEC. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update these forward-looking statements. Any future product, feature or related specification that may be referenced in this release are for information purposes only and are not commitments to deliver any technology or enhancement. Riverbed reserves the right to modify future product plans at any time.

About Riverbed

Riverbed at more than $1 billion in annual revenue is the leader in Application Performance Infrastructure, delivering the most complete platform for Location-Independent Computing. Location-Independent Computing turns location and distance into a competitive advantage by allowing IT to have the flexibility to host applications and data in the most optimal locations while ensuring applications perform as expected, data is always available when needed, and performance issues are detected and fixed before end users notice. Riverbed’s 25,000+ customers include 97% of the Fortune 100 and 95% of the Forbes Global 100. Learn more at www.riverbed.com.

Riverbed and any Riverbed product or service name or logo used herein are trademarks of Riverbed Technology, Inc. All other trademarks used herein belong to their respective owners.

Friday, February 28th, 2014 Uncategorized Comments Off on (RVBD) Board of Directors Rejects Unsolicited Proposal from Elliott

(LIVE) Uses (GOOG) Model to Drive Traffic and Revenue

BALTIMORE, February 28, 2014  —

Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, announced today that it has issued a new research update on online deal pioneer LiveDeal, Inc. (NASDAQ – LIVE). LiveDeal provides marketing solutions that boost customer awareness and merchant visibility on the Internet, primarily through its innovative deal engine.

In the Opportunity Research update, analyst Rob Goldman outlines his thesis on LiveDeal.

“Since our initiation of coverage report two weeks ago, LiveDeal has executed a series of steps that affirms our thesis and gives us even greater confidence in our short term and long term price objectives.  For example, the Company is flush with cash from a $10 million funding, and will soon introduce new mobile apps enabling users to have immediate access to LiveDeal’s “instant” real-time deal platform http://www.LiveDeal.com.”

“We view these steps are a strong complement to the Company’s core business and revenue models which are preferred by restaurateurs to Groupon and other deal sites. More important, LiveDeal’ Google-type search engine model drives web traffic and revenue, and carries higher profit margins than typical deal sites. It also doesn’t hurt to have Howard Stern aiding in a large ad campaign around the time the Company launches its services in New York City given his long history of sponsorship successes.”

This press release contains excerpts of our most recently published sponsored update on LiveDeal, Inc. Goldman Small Cap Research sponsored articles, reports, and updates as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting http://www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters.  Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit http://www.goldmanresearch.com.

About LiveDeal, Inc. (NASDAQ  LIVE): LiveDeal Inc. provides marketing solutions that boost customer awareness and merchant visibility on the Internet. LiveDeal operates a deal engine, which is a service that connects merchants and consumers via an innovative platform that uses geo-location, enabling businesses to communicate real-time and instant offers to nearby consumers. In November 2012, LiveDeal commenced the sale of marketing tools that help local businesses manage their online presence under the Company’s Velocity Local™ brand. LiveDeal continues to actively develop, revise, and evaluate these products and services and its marketing strategies and procedures. For more information, please visit http://www.LiveDeal.com.

Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
rob@goldmanresearch.com

Friday, February 28th, 2014 Uncategorized Comments Off on (LIVE) Uses (GOOG) Model to Drive Traffic and Revenue

(CETV) Refinancing of 2016 Notes With Proceeds From a Rights Offering, Financing by Time Warner

HAMILTON, Bermuda, Feb. 28, 2014  — Central European Media Enterprises Ltd. (“CME“) (Nasdaq:CETV) (Prague Stock Exchange:CETV) announced today that, to finance the redemption of its EUR 272,972,000 aggregate principal amount of 11.625% senior notes due 2016 (the “2016 Notes“) and to provide additional liquidity, CME has entered into agreements with Time Warner Inc. and one of its affiliates (together, “Time Warner“) and filed a rights offering registration statement. The rights offering and related transactions to be undertaken pursuant to these agreements are subject to certain conditions described below.

In connection with the rights offering, CME shareholders holding Class A Common Stock and Preferred Stock (allocated on an as-converted basis) will receive non-transferrable rights to purchase in the aggregate 3,391,403 units at a subscription price of $100.00 per unit. Shareholders will receive one right per 62.5 shares of Class A Common Stock held as of a record date to be determined at a later date and subsequently announced. Only shareholders holding 62.5 or more shares of Class A Common Stock on the record date will satisfy the minimum subscription threshold and be eligible to participate in the rights offering. Each unit will consist of a 15.0% Senior Secured Note due 2017 in the original principal amount of $100.00 (the “New Notes“) and 21.167376 unit warrants. Interest on the New Notes will be paid in arrears (a) on each interest payment date (June 1 and December 1 of each year) on or prior to November 15, 2015 by adding the amount of such interest to the principal balance of the New Notes and (b) on each interest payment date thereafter, at the option of CME, either (i) entirely in cash or (ii) by increasing the principal amount of the New Notes. Each unit warrant will entitle the warrant holder to purchase one share of CME’s Class A Common Stock at an exercise price of $1.00 per share.

Time Warner has agreed to purchase all units in the rights offering not subscribed for by other shareholders. In addition, Time Warner will purchase 576,968 units from CME in a separate private placement transaction to close contemporaneously with the rights offering. In connection with the foregoing, CME will issue a warrant to Time Warner to purchase 30 million shares of Class A Common Stock at an exercise price of $1.00 per share.

The Company expects to raise gross proceeds from the rights offering and the purchase of units by Time Warner of approximately $396.8 million, which is equal to the amount of principal and early redemption premium payable to redeem the 2016 Notes (at February 21, 2014 exchange rates). In addition, CME will issue 84 million unit warrants in the rights offering and the Time Warner private placement.

If the rights offering has closed prior to May 29, 2014, Time Warner will, under a term loan facility entered into today, fund a loan to CME on the date of the closing of the rights offering in the amount of $30.0 million that matures on December 1, 2017. If the rights offering has not closed prior to May 29, 2014, Time Warner will under such term loan facility loan to CME the amount required to redeem the 2016 Notes plus an additional $30.0 million, all of which will initially mature on September 8, 2014. If the rights offering closes after May 29, 2014 but before September 8, 2014, CME will use the proceeds of the rights offering to repay a portion of the term loan used to redeem the 2016 Notes, and the maturity date of the remaining portion of the term loan will be extended to December 1, 2017. If the rights offering has not closed by September 8, 2014, then CME will issue to Time Warner warrants to purchase 84 million shares of Class A Common Stock, which equal the number of unit warrants that otherwise would have been issued in the rights offering and Time Warner private placement. Upon the issuance of such warrants, the maturity date of the term loan facility will be extended to December 1, 2017.

In addition, Time Warner will provide to CME a $115.0 million senior secured revolving credit facility available to CME at the earlier of the closing of the rights offering and the funding of the term loan.

The issuance of the New Notes and the incurrence of debt under the term loan and revolving credit facilities are subject to the consent of the holders of the 9.0% Senior Secured Notes due 2017 issued by the Company’s wholly owned subsidiary, CET 21 spol. s r.o. Today CME also announced the commencement by CET 21 spol. s r.o. of a consent solicitation to permit, among other things, certain of the indebtedness expected to be incurred as a result of the transactions that we announced today.

The principal purpose of these financing transactions is to enhance CME’s overall liquidity and cash flow by refinancing the remaining 2016 Notes, which are cash pay indebtedness, with non-cash pay indebtedness, including the New Notes, and to provide funds for general corporate purposes.

The rights offering and issuance of related warrants to Time Warner are subject to approval by CME’s shareholders and satisfaction of certain customary closing conditions.

A registration statement (including a prospectus) with respect to rights, units to be issued upon exercise of rights, New Notes and warrants underlying the units, and shares of Class A Common Stock issuable upon exercise of warrants has been filed with the Securities and Exchange Commission (the “SEC“), but has not yet become effective. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. A copy of the most recent prospectus included in the registration statement can be accessed on our website at www.cme.net. Please see “Additional Information Regarding the Proposed Transactions and Certain Participants” below for additional information.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any offer or sale of such securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About CME

CME is a media and entertainment company operating leading businesses in six Central and Eastern European markets with an aggregate population of approximately 50 million people. CME broadcasts television channels in Bulgaria (bTV, bTV Cinema, bTV Comedy, bTV Action, bTV Lady, bTV Lady+1, Ring.bg and Ring.bg+1), Croatia (Nova TV, Doma, Nova World and Mini TV), the Czech Republic (TV Nova, Nova Cinema, Nova Sport, Fanda, Smichov and Telka), Romania (PRO TV, PRO TV International, Acasa, Acasa Gold, PRO Cinema, Sport.ro, MTV Romania, PRO TV Chisinau and Acasa Moldova), the Slovak Republic (TV Markíza, Doma and Dajto), and Slovenia (POP TV, Kanal A, Brio, Oto and Kino). CME is traded on the NASDAQ Global Select Market and the Prague Stock Exchange under the ticker symbol “CETV”.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements related to the offering and the expected use of the net proceeds therefrom, which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases, which are predictions of or indicate future events or trends and which do not relate solely to historical matters. While forward-looking statements reflect CME’s good faith beliefs, assumptions and expectations, they are not guarantees of future performance. Furthermore, CME disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions, new information or other changes. Known material risks, uncertainties and other factors that can affect future results are discussed or incorporated by reference in the registration statement and periodic reports under the Securities Exchange Act of 1934, as amended, filed by CME from time to time with the SEC.

Additional Information Regarding the Proposed Transactions and Certain Participants

The registration statement relating to the rights offering has not yet become effective and no securities may be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. CME intends to commence the rights offering promptly after the registration statement has been declared effective by the SEC. The terms and conditions of the rights offering will be made available to CME’s shareholders once the rights offering has commenced. CME has not yet set a record date for the rights offering. A copy of the prospectus relating to the rights offering meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and additional materials relating to the rights offering will be mailed to shareholders of record of CME shortly after the record date. Shareholders will then also be able to obtain a copy of this prospectus from the subscription and information agent for the rights offering.

In connection with the proposed transaction, CME has filed with the SEC, but not yet distributed to shareholders, a preliminary proxy statement and will mail or otherwise disseminate the proxy statement and a form of proxy to its shareholders when it is finalized. Shareholders and investors are encouraged to read the proxy statement (and other relevant materials) regarding the proposed transaction carefully and in its entirety when it becomes available, and before making any voting decision, as it will contain important information about the transaction. shareholders and investors will be able to obtain a free copy of the proxy statement, when available, as well as other filings made by CME regarding Central European Media Enterprises Ltd.and the proposed transaction at the SEC’s website at http://www.sec.gov and CME’s website at www.cme.net.

Additionally, CME and its directors and executive officers and Time Warner may be deemed, under SEC rules, to be participants in the solicitation of proxies from CME’s shareholders with respect to the approval by the shareholders of the rights offering and the issuance of the related Warrants to Time Warner. Shareholders may obtain information regarding the names, affiliations and interests of such individuals in CME’s preliminary proxy statement filed in connection with the proposed transactions filed with the SEC on February 28, 2014. These documents may be obtained free of charge from the SEC’s website at www.sec.gov and CME’s website at www.cme.net.

CONTACT: For further information, please contact:

         Mark Kobal
         Head of Investor Relations
         Central European Media Enterprises
         Krizeneckeho nam. 1078/5
         152 00 Praha 5
         Czech Republic
         +420 242 465 576
         mark.kobal@cme.net
Friday, February 28th, 2014 Uncategorized Comments Off on (CETV) Refinancing of 2016 Notes With Proceeds From a Rights Offering, Financing by Time Warner

(VNRX) Completes $3 Million Private Placement

NAMUR, BELGIUM–(Feb 28, 2014) – VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced the completion of a private placement to selected existing and new accredited investors of 1.5 million shares of common stock at a price of $2.00 per share, as well as five-year warrants to purchase up to an additional 1.5 million shares of common stock at an exercise price of $2.20 per share, which resulted in gross proceeds to VolitionRx of $3 million. Lake Street Capital Markets, LLC acted as exclusive US placement agent on this transaction.

Cameron Reynolds, CEO of VolitionRx, says: “Proceeds from this raise will be used to fund operating costs, including VolitionRx’s ongoing clinical trials program, notably our 4,800-individual colorectal cancer trial, for which analysis commenced in January. We plan to use data from the trial in the initial application for European regulatory approval for our first cancer diagnostic test, which will be for colorectal cancer.”

The private placement was made only to accredited investors in accordance with Section 4(2) under the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations promulgated thereunder. The securities sold in the private placement have not been registered under the Securities Act of 1933 or any state securities laws and unless so registered may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933 and applicable state securities laws. In connection with the private placement, VolitionRx has agreed, subject to certain terms and conditions, to file a registration statement to register for resale of the common stock issued in the private placement (including the shares issuable upon exercise of the warrants). This announcement is neither an offer to sell nor a solicitation of an offer to buy any of the securities issued in the private placement and is being issued under Rule 135c under the Securities Act.

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream — an indication that cancer is present.

VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide. Additional information can be found on VolitionRx’s website www.volitionrx.com

Safe Harbor Statement

Statements in this press release may be “forward-looking statements”. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

Media Contacts:
Charlotte Reynolds
VolitionRx
Telephone: +44 (0) 795 217 7498
Email: Charlotte.Reynolds@volitionrx.com

Jon Falcone
Racepoint Group
Telephone: +44 (0) 208 811 2128
Email: Jon.Falcone@racepointgroup.com

Investor Contacts:
Kirin M. Smith
ProActive Capital
Telephone: +1 646 863 6519
Email: mksmith@proactivecapital.com

Friday, February 28th, 2014 Uncategorized Comments Off on (VNRX) Completes $3 Million Private Placement

(CTIC) NICE Publishes Final Guidance on PIXUVRI® (pixantrone)

– Published Final Guidance Recommending PIXUVRI as Cost Effective and Provides Patients with Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Greater Access to Only Approved Therapy –

SEATTLE, Feb. 27, 2014  — Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has published final guidance recommending prescription of PIXUVRI® (pixantrone) as a cost-effective monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), which includes diffuse large B-cell lymphoma. CTI estimates that there are approximately 1,600 to 1,800 people in the UK diagnosed with multiply relapsed aggressive B-cell NHL per year.

“NICE’s final guidance on PIXUVRI means that physicians in England and Wales now have access to the only approved therapy for their patients with aggressive B-cell NHL in the third- and fourth-line salvage setting,” James A. Bianco, M.D., President and Chief Executive Officer of CTI. “We hope the NHS commissioners will recognize the lack of suitable treatment options that exist for patients at this stage of the disease and list PIXUVRI on hospital formularies as soon as possible.”

The final guidance determines PIXUVRI cost effective and recommends prescription of PIXUVRI as an option for certain people with histologically confirmed aggressive B-cell NHL, who have previously received rituximab and are receiving PIXUVRI as a third- or fourth-line treatment, for as long as CTI makes the Patient Access Scheme (PAS) available. The PAS is a confidential pricing and access agreement with the United Kingdom’s Department of Health.

Publication of the final guidance by NICE follows the final appraisal determination, or FAD, that was issued in January 2014. Now that the final guidance is published, the NHS is expected to implement it within 90 days. CTI expects to officially launch PIXUVRI in England and Wales this spring, after the FAD has been largely implemented. For more information on NICE’s final guidance, go to www.pixuvri.eu.

About PIXUVRI (pixantrone)
PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Unlike related compounds, PIXUVRI forms stable DNA adducts and in preclinical models has superior anti-lymphoma activity compared to related compounds. PIXUVRI was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite — both of which are the putative mechanisms for anthracycline induced acute and chronic cardiotoxicity. These novel pharmacologic properties allow PIXUVRI to be administered to patients with near maximal lifetime exposure to anthracyclines without unacceptable rates of cardiotoxicity.

In May 2012, the European Commission (EC) granted conditional marketing authorization for PIXUVRI as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL. The benefit of PIXUVRI treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy. The Summary of Product Characteristics (SmPC) has the full prescribing information, including the safety and efficacy profile of PIXUVRI in the approved indication. The SmPC is available at www.pixuvri.eu. PIXUVRI does not have marketing approval in the United States.

About NHL
NHL is the sixth most common cancer in the UK; in 2010, 12,180 people were diagnosed with the disease.1 NHL is caused by the abnormal proliferation of lymphocytes, cells that are key to the functioning of the immune system. It usually originates in lymph nodes and spreads through the lymphatic system. NHL can be broadly classified into two main forms—aggressive and indolent NHL. Aggressive NHL is a rapidly growing form of the disease that moves into advanced stages much faster than indolent NHL, which progresses more slowly.

There are many subtypes of NHL, but aggressive B-cell NHL is the most common and accounts for about 55 percent of NHL cases.2 After initial therapy for aggressive NHL with anthracycline-based combination therapy, one-third of patients typically develop progressive disease.3 Approximately half of these patients are likely to be eligible for intensive second-line treatment and stem cell transplantation, although 50 percent are expected not to respond.3 For those patients who fail to respond or relapse following second-line treatment, treatment options are limited, and usually palliative only.3

About Conditional Marketing Authorization
Similar to accelerated approval regulations in the United States, conditional marketing authorizations are granted in the E.U. to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit. A conditional marketing authorization is renewable annually. Under the provisions of the conditional marketing authorization for PIXUVRI, CTI will be required to complete a post-marketing study aimed at confirming the clinical benefit previously observed.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who have relapsed after one to three prior regimens for aggressive B‑cell NHL and who are not eligible for autologous stem cell transplant. As a condition of approval, CTI has agreed to have available the PIX306 clinical trial results by June 2015.

About Cell Therapeutics, Inc.
CTI (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI’s securities. Such statements include, but are not limited to, statements regarding the expected number of people in the UK with multiply relapsed aggressive B-cell NHL per year, expectations with respect to the development of CTI and its product and product candidate portfolio, the expected benefits and effectiveness of PIXUVRI, NHS’ processes, pricing arrangements and the cost-effectiveness and availability of PIXUVRI to patients in the United Kingdom. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI cannot predict or guarantee the outcome of preclinical and clinical studies, that CTI may not obtain reimbursement for PIXUVRI in certain markets in the European Union as planned, that the conditional marketing authorization for PIXUVRI may not be renewed, that the second Phase 3 clinical trial of pacritinib will not occur as planned, that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities, that CTI may experience delays in the commencement of preclinical and clinical studies, risks related to the costs of developing, producing and selling PIXUVRI, pacritinib, and CTI’s other product candidates, and other risks, including, without limitation, competitive factors, technological developments, that CTI’s operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI may not achieve previously announced goals and objectives as or when projected, that CTI’s average net operating burn rate may increase, that CTI will continue to need to raise capital to fund its operating expenses, but may not be able to raise sufficient amounts to fund its continued operation as well as other risks listed or described from time to time in CTI’s most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K. Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

PIXUVRI is a registered trademark of Cell Therapeutics, Inc.

References:

1. Cancer Research UK http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/commoncancers/ Accessed April 2013.
2. Harris NL, et al. Ann Oncol. 1999;10(12):1419-32
3. Friedberg ASH Education Book 2011;1:498-505

Contacts:

Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
ebell@ctiseattle.com

In Europe
CTI Life Sciences Limited, Milan Branch
Laura Villa
E: lvilla@cti-lifesciences.com
T: +39 02 89659706

http://www.celltherapeutics.com/italiano

Thursday, February 27th, 2014 Uncategorized Comments Off on (CTIC) NICE Publishes Final Guidance on PIXUVRI® (pixantrone)

(ASYS) $10M in Orders from Solar Tech Leaders; 2nd PECVD Production Order

TEMPE, Ariz., Feb. 27, 2014  — Amtech Systems, Inc. (NASDAQ: ASYS), a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and sapphire and silicon wafers, today announced it has received approximately $10 million in new solar orders, including orders for its diffusion and PECVD systems from respected solar technology leaders in Korea and Taiwan.  The orders are expected to ship within the next six months.

Mr. Fokko Pentinga, Chief Executive Officer of Amtech, commented, “We are very pleased to see this new demand for our products from solar technology leaders in Asia.   These industry leaders reflect the increasing demand for solar technology solutions and a renewed market interest in adding new, highly productive capacity to meet the goal of higher solar cell efficiency at a lower total cost of ownership.  We continue to have discussions with both current and potential new customers about our leading-edge technology solutions including our ion implant system, N-type and PECVD technologies.  We are proud of securing the second PECVD production order, and believe our new PECVD system alone has the potential to more than double our served available market.”

About Amtech Systems, Inc.

Amtech Systems, Inc. manufactures capital equipment, including silicon wafer handling automation, thermal processing and ion implant equipment and related consumables used in fabricating solar cells, LED and semiconductor devices. Semiconductors, or semiconductor chips, are fabricated on silicon wafer substrates, sliced from ingots, and are part of the circuitry, or electronic components, of many products including solar cells, computers, telecommunications devices, automotive products, consumer goods, and industrial automation and control systems. The Company’s wafer handling, thermal processing and consumable products currently address the diffusion, oxidation, and deposition steps used in the fabrication of solar cells, LEDs, semiconductors, MEMS and the polishing of newly sliced silicon wafers.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained in this press release is forward-looking in nature. All statements in this press release, or made by management of Amtech Systems, Inc. and its subsidiaries (“the Company” or “Amtech”), other than statements of historical fact, are hereby identified as “forward-looking statements” (as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “would,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology.  Examples of forward-looking statements include statements regarding Amtech’s future financial results, operating results, business strategies, projected costs, products under development, competitive positions and plans and objectives of the Company and its management for future operations.

We cannot guarantee that any forward-looking statement will be realized, although we believe that the expectations reflected in the forward-looking statements are reasonable. Achievement of future results is subject to risks, uncertainties and potentially inaccurate assumptions. The Form 10-K that we filed with the Securities and Exchange Commission for the year-ended September 30, 2013 listed various important factors that could affect Amtech’s future operating results and financial condition and could cause actual results to differ materially from historical results and expectations based on forward-looking statements made in this document or elsewhere by Amtech or on its behalf.  These factors can be found under the heading “Risk Factors” in the Form 10-K and investors should refer to them.  Because it is not possible to predict or identify all such factors, any such list cannot be considered a complete set of all potential risks or uncertainties.  Except as required by law, we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

Amtech Systems, Inc.
Bradley C. Anderson
Chief Financial Officer
(480) 967-5146irelations@Amtechsystems.com
Christensen
Investor Relations
Patty Bruner
(480) 201-6075pbruner@christensenir.com
Thursday, February 27th, 2014 Uncategorized Comments Off on (ASYS) $10M in Orders from Solar Tech Leaders; 2nd PECVD Production Order

(FATE) to Present at Upcoming March Conferences

SAN DIEGO, Feb. 27, 2014  — Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company’s programs and outlook at the following March conferences:

  • Cowen & Company 34th Annual Healthcare Conference at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 5, 2014 at 8:00 a.m. EST.
  • 26th Annual ROTH Conference at the Ritz-Carlton Laguna Niguel, CA on Monday, March 10, 2014 at 5:00 p.m. PDT.
  • Alliance for Regenerative Medicine (ARM) 2nd Annual Regen Med Investor Day at the Metropolitan Club in New York, NY, on Wednesday, March 26, 2014 at 1:00 p.m. EDT.

Live webcasts for each event can be accessed under “Events & Presentations” in the Investors and Media section of the Company’s website at www.fatetherapeutics.com. Archived replays of webcasts will be available on the Company’s website for 30 days after each conference.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including certain hematologic malignancies, lysosomal storage disorders and muscular dystrophies. The Company utilizes established pharmacologic modalities, including small molecules and therapeutic proteins, and well-characterized biological mechanisms to enhance the therapeutic potential of adult stem cells. The Company has built two adult stem cell modulation platforms: a hematopoietic stem cell (HSC) modulation platform, which seeks to optimize the therapeutic potential of HSCs for treating patients with hematologic malignancies and rare genetic disorders that are undergoing hematopoietic stem cell transplantation, and a muscle satellite stem cell modulation platform, which seeks to activate the regenerative capacity of muscle for treating patients with degenerative muscle disorders. The Company is presently advancing its lead product candidate, ProHema®, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood, in which is in Phase 2 clinical development for hematologic malignancies. Fate Therapeutics is also advancing its proprietary Wnt7a protein analogs in preclinical development for the treatment of muscular dystrophies. Fate Therapeutics is headquartered in San Diego, CA.   For more information, please visit www.fatetherapeutics.com.

CONTACT: Paul Cox, Stern Investor Relations, Inc.
         212.362.1200, paul@sternir.com
Thursday, February 27th, 2014 Uncategorized Comments Off on (FATE) to Present at Upcoming March Conferences

(PTX) Agreement w/ Osmotica to Promo KHEDEZLA in Major Depressive Disorder

Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that it has signed an agreement with Osmotica Pharmaceuticals Corp (“Osmotica”) to market and sell KHEDEZLA™ (desvenlafaxine) Extended-Release (ER) Tablets, 50 mg and 100 mg. The sales and marketing of KHEDEZLA will be supported by Pernix’s team of approximately 90 sales professionals, promoting the product to high desvenlafaxine prescribing physicians. The New Drug Application (NDA) for KHEDEZLA Tablets was approved by the U.S. Food and Drug Administration pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act in July 2013. KHEDEZLA is indicated for the treatment of major depressive disorder (MDD).

“We are pleased to add KHEDEZLA to the Pernix product portfolio,” said Doug Drysdale, Chairman and CEO of Pernix. “KHEDEZLA provides Pernix with an opportunity to leverage its greatest asset – our team of 90 professional sales men and women and represents the first step in our transformation to specialist promotion. KHEDEZLA has excellent promotional synergy with our sleep maintenance product, SILENOR. We believe that the ability to promote SILENOR and KHEDEZLA side by side provides a valuable product offering to Pernix’s target physicians.”

The KHEDEZLA NDA included comparative bioequivalence testing against Pfizer’s PRISTIQ® (desvenlafaxine) Extended-Release Tablets. According to IMS Health data, annual U.S. sales of PRISTIQ are approximately $614 million. Under terms of its agreement with Osmotica, Pernix will market, sell and distribute KHEDEZLA in the United States. Pernix and Osmotica will share profits from the sales of the product. The transaction was completed without the use of any proceeds from Pernix’s recently closed Senior Notes 2019 offering.

Important Information about KHEDEZLA ER Tablets

A black box warning is associated with this product regarding increased risk of suicidal thoughts and behaviors in children, adolescents and young adults taking antidepressants. All persons taking KHEDEZLA should be monitored for worsening and emergence of suicidal thoughts and behaviors. KHEDEZLA is not approved for use in pediatric patients. Refer to full prescribing information for complete boxed warning.

KHEDEZLA (desvenlafaxine) Extended-release Tablets are contraindicated in patients who are hypersensitive to desvenlafaxine succinate, venlafaxine hydrochloride or to any component of the product. Angioedema has been reported in patients treated with desvenlafaxine. The use of MAOIs intended to treat psychiatric disorders with KHEDEZLA or within 7 days of stopping treatment with KHEDEZLA is contraindicated because of an increased risk of serotonin syndrome. The use of KHEDEZLA within 14 days of stopping a MAOI intended to treat psychiatric disorders is also contraindicated. Starting KHEDEZLA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: CEDAX®, an antibiotic for middle ear infections and a number of treatments for cough and cold conditions including ZUTRIPRO®, REZIRA® and VITUZ®. The Company also markets SILENOR, a non-narcotic product for the treatment of insomnia. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. The Company’s wholly owned subsidiary, Pernix Manufacturing, manufactures and packages products for the pharmaceutical industry in a wide range of dosage forms. Founded in 1996, the Company is based in Houston, TX.

Additional information about Pernix is available on the Company’s website located at www.pernixtx.com.

About Osmotica Pharmaceutical Corp.

Osmotica Pharmaceutical is a global specialty pharmaceutical company with a proven history of developing commercially successful pharmaceutical products. The company uses its proprietary osmotic technology platform and with strategic partners develops and commercializes high quality pharmaceutical products. In addition to the products currently on the market, the company’s pipeline includes numerous ANDA programs and several innovative neurology-based NDA programs.

Osmotica Pharmaceutical and its related companies form an international group of companies with principal operations located in the United States, Argentina and Hungary.

For more information on the Company, please visit Osmotica’s website at www.osmotica.com.

Cautionary Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “target” or similar expressions are forward-looking statements. Because these statements reflect the Company’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect the Company’s future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in the Company’s Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Thursday, February 27th, 2014 Uncategorized Comments Off on (PTX) Agreement w/ Osmotica to Promo KHEDEZLA in Major Depressive Disorder

(AERI) to Present at the Cowen and Company 34th Annual Health Care Conference

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) today announced that the Company will present at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4th at 10:40 a.m. Eastern Time in Boston, MA.

The presentation will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com/. A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The Company is preparing for two Phase 3 registration trials, where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for AR-13324 (dosed once daily) compared to timolol (dosed twice daily). The Company also started a Phase 2b clinical trial of its fixed-dose combination product PG324, where the primary efficacy endpoint will be to demonstrate superiority of PG324 to each of its components.

Thursday, February 27th, 2014 Uncategorized Comments Off on (AERI) to Present at the Cowen and Company 34th Annual Health Care Conference

(COA) Essilor International Agrees to Acquire for $430 Million

VANCOUVER, British Columbia, Feb. 27, 2014  — Coastal Contacts Inc. (“Coastal.com” or “the Company”) (Nasdaq:COA) (TSX:COA), a leading global manufacturer and digital retailer of high-quality glasses and contact lenses, announced today that it has entered into an Acquisition Agreement with Essilor International under which Essilor has agreed to acquire all of the issued and outstanding common shares of Coastal.com for a purchase price of CAD$12.45 per share, representing a net equity value of approximately CAD$430 million.

The purchase price per share represents a premium of 43% over the three month volume-weighted average price of CAD$8.73 on the TSX and 84% over the six month volume-weighted average price of CAD$6.78.

“Essilor shares Coastal.com’s focus on customers, innovation and growth”, said Roger Hardy, Coastal.com’s founder and CEO. “The combination will enhance Coastal.com’s ability to achieve its goals while realizing a significant all-cash premium for our shareholders. I am confident this transaction is the right decision for Coastal.com, our employees and our shareholders.”

The transaction will be implemented by way of a statutory plan of arrangement and is subject to customary closing conditions, including approval by shareholders, court approval and regulatory approval. Assuming the timely receipt of such approvals, the transaction is expected to close in the second quarter of 2014.

The Board of Directors of Coastal.com, acting on the recommendation of its independent special committee and after consultation with its legal and financial advisors, unanimously approved the Acquisition Agreement and recommend that shareholders of Coastal.com vote their common shares in favour of the Arrangement. Members of the Board and officers of Coastal.com collectively holding over 16% of the outstanding common shares of Coastal.com have also entered into support and voting agreements with Essilor.

The Acquisition Agreement provides for a customary non-solicitation covenant on the part of Coastal.com and, in the event of a superior proposal, Essilor has the right to either match the superior proposal or receive a termination fee in the amount of CAD$16 million.

Further details regarding the terms of the Arrangement are set out in the Acquisition Agreement, which will be publicly filed by Coastal.com with the Canadian securities regulatory authorities on SEDAR at http://www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at http://www.sec.gov. In addition, details of the Arrangement, including a summary of the terms and conditions of the Acquisition Agreement, will be disclosed in a management information circular of Coastal.com, which will be mailed to shareholders and will also be available on SEDAR and EDGAR. Shareholders are urged to carefully read the information circular once it becomes available.

Financial and Legal Advisors

Guggenheim Securities LLC acted as lead financial advisor and Roth Capital Partners as co-financial advisor and McCarthy Tétrault LLP is acting as legal advisor to Coastal.com in connection with the transaction. Neal, Gerber & Eisenberg LLP is acting as special U.S. counsel to Coastal.com. BMO Capital Markets is acting as financial advisor and Blake, Cassels & Graydon LLP is acting as legal advisor to the Special Committee.

About Essilor

The world’s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor’s flagship brands are Varilux®, Crizal®, Definity®, Xperio®, OptifogTM, Foster Grant®, Bolon® and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of over €5 billion in 2013 and employs more than 55,000 people. It operates in some 100 countries with 28 plants, more than 450 prescription laboratories and edging facilities, as well as several research and development centers around the world. For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

About Coastal.com

Coastal.com is a leading manufacturer and online retailer of eyewear products offered through a family of world class websites.  Established in 2000, the Coastal.com family of brands offers an extensive, in stock selection of prescription eyewear, contact lenses and sunglasses. Coastal.com’s vision is to make the process simple, either on-line or at one of our retail showrooms, so our customers can see everything life has to offer.  For more information about Coastal.com, please visit www.coastal.com.

Cautionary Note Regarding Forward-Looking Statements

All statements made in this news release which are not current statements or historical facts constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” as defined in Section 27A of the United States Securities Act of 1933, Section 21E of the United States Securities Exchange Act of 1934, the Private Securities Litigation Reform Act of 1995, or in releases made by the United States Securities and Exchange Commission, all as may be amended from time to time, and the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “goal”, “target”, “should”, “likely”, “potential”, “continue”, “project”, “forecast”, “prospects”, and similar expressions typically are used to identify forward-looking information and statements.

Forward-looking information and statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the Arrangement, Coastal.com’s business and the industry and markets in which it operates. Forward-looking information and statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. You are cautioned that forward-looking information and statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond Coastal.com’s control that could cause Coastal.com’s actual future results or performance to be materially different from those that are disclosed in or implied by the forward-looking information. These factors include, but are not limited to, risks and uncertainties associated with the timely receipt of required shareholder, court and regulatory approvals in connection with the Arrangement; changes in the market; potential downturns in economic conditions; consumer credit risk; Coastal.com’s ability to implement its business strategies; competition from traditional and online retailers; limited suppliers; limited availability of inventory; disruption in Coastal’s distribution facilities; mergers and acquisitions; foreign currency exchange rate fluctuations; regulatory requirements; demand for contact lenses, eyeglasses and related vision care products; the risk that Coastal.com will not be successful in defending against litigation; dependence on the Internet; and the other risks detailed in Coastal.com’s filings with the Canadian securities regulatory authorities.

You should not place undue reliance on forward-looking information and statements which are qualified in their entirety by this cautionary note. Forward-looking information and statements in this news release are made as of the date hereof and Coastal.com expressly disclaims any intent or obligation to update such forward-looking information or statements, unless Coastal.com specifically states otherwise or as required by applicable law.

For a complete discussion of the assumptions, risks and uncertainties related to Coastal.com’s business, you are encouraged to review Coastal.com’s filings with the Canadian securities regulatory authorities filed on SEDAR at http://www.sedar.com.

CONTACT: Terry Vanderkruyk
         Chief Corporate Development Officer
         Coastal.com
         (604) 676-4498
         terryv@coastal.com

         or

         Liolios Group, Inc.
         Scott Liolios or Cody Slach
         (949) 574-3860
         COA@liolios.com
Thursday, February 27th, 2014 Uncategorized Comments Off on (COA) Essilor International Agrees to Acquire for $430 Million

(CTRL) Expands Home Security Solutions through Partnerships with Device Manufacturers

Control4 Corporation (NASDAQ: CTRL), a leading provider of automation and control solutions for the connected home, today announced that it is now providing customers with a much broader array of home security personalization options through simple integration with the top brands of security cameras and network video recorders (NVRs) on the market. The increased surveillance camera and NVR support results from the implementation of Control4’s Simple Device Discovery Protocol (SDDP) by five of the leading security monitoring manufacturers: LILIN, Channel Vision, Planet, QNAP and SnapAV. SDDP enables device interoperability and integration with Control4® systems for a seamless and efficient experience from start to finish.

Consumers increasingly rely on surveillance cameras and NVRs to bolster the security of their homes and businesses. Integrating these security solutions into a Control4 automation system helps consumers better protect their homes and businesses by providing remote viewing of the property from any location at any time via smart connected devices, such as smartphones and tablets and the Control4 4Sight service. Consumers can have their smart home or business set to respond to “actions” identified by the security camera, such as sending text alerts to the owner when a person approaches the door; or if a door is opened late at night, automatically triggering the lights to flash, loud music to play, and alarms to sound. Homeowners can also view security camera footage right from their mobile devices and remotely connect to and command the home, which delivers additional peace of mind.

“We’ve seen a significant uptick in the integration of security and surveillance into Control4 systems in recent years — in fact, a growing percentage of all Control4 projects now include some form of security,” said Paul Williams, Control4 Vice President of Security & Communications. “With the expanded support for surveillance cameras and NVRs, Control4 customers can work with their dealers to develop a customized, integrated security solution to monitor and protect their homes, families and businesses.”

Control4 enhances the security system experience of smart homes and smart businesses by making it easy to integrate cameras and NVRs into a homeowner’s Control4 automation system. Control4 integrates security solutions, smart locks, sensors, lighting and remote monitoring through the 4Sight service along with other home automation capabilities to provide customers with a broad range of home security configurations.

For more information about Control4’s security solutions, please visit: www.control4.com.

About Control4

Control4 (CTRL) is a leading provider of automation systems for homes and businesses, offering personalized control of lighting, music, video, temperature, security, communications and similar functionalities into a unified automation solution that enhances the daily lives of its customers. Control4 unlocks the potential of connected devices, making entertainment systems easier to use, homes more comfortable and energy efficient, and families more secure. More than 75% of Control4’s consumers have integrated two or more functionalities with Control4’s solution, which is available through more than 3,000 custom integrators, retail outlets, and distributors in over 80 countries. By delivering insightfully simple control solutions that enhance the lives of individuals and families, Control4 is the automation platform of choice for consumers, major consumer electronics companies, hotels, and businesses around the world.

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding Control4’s possible future products and financial outlook. All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Control4’s control. Control4’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in Control4’s most recent S-1/A filed with the Securities and Exchange Commission, as well as other documents that may be filed by the company from time to time with the Securities and Exchange Commission. Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent Control4’s views as of the date of this press release. The company anticipates that subsequent events and developments may cause its views to change. Control4 has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing Control4’s views as of any date subsequent to the date of this press release.

Wednesday, February 26th, 2014 Uncategorized Comments Off on (CTRL) Expands Home Security Solutions through Partnerships with Device Manufacturers

(RSYS) and Octasic Partner to Deliver 3G and LTE Small Cell Solutions

Octasic’s New OCTBTS Platforms Integrate Radisys’ Femtotality and TOTALeNodeB Small Cell Software

BARCELONA, SPAIN–(Feb 26, 2014) – Mobile World Congress — Radisys Corporation (NASDAQ: RSYS), a market leader enabling wireless infrastructure solutions, and Octasic, Inc., a leading provider of devices and technology platforms for wireless base stations and media processing, today announced the integration of Radisys’ Trillium® small cell software with its new OCTBTS platforms, including the OCTBTS 3000 — the smallest full-mobility base station in the world. Octasic’s platforms leverage Radisys’ Femtotality 3G small cell software today, with plans to integrate its LTE TOTALeNodeB™ small cell software.

“The combination of our OCTBTS platforms and Radysis’ Trillium software makes for a powerful 3G small cell, which clients are increasingly turning to for a variety of applications in public and private networks,” commented Michel Laurence, president, Octasic. “We are rapidly adding new clients to our OCTBTS user base, and the stability and performance of the Radisys software has boosted the confidence of our clients and helped motivate uptake of the platform.”

Radisys’ Trillium® TOTALeNodeB software is a turn-key, deployment proven small cell solution that dramatically simplifies the development and integration of LTE small cells while cutting the typical product development time in half. It enables customers to leverage one software solution that can support all small cell deployments across the network, from residential cells that support up to eight users to Pico cells that support 100+ users. This scalability enables rapid deployment.

Octasic’s OCTBTS family of base station platforms are ready-to-deploy Software Defined Radio (SDR) systems powered by the OCT2224W small cell system-on-a-chip (SoC). The OCTBTS platforms incorporate Octasic’s flexiPHY layer 1 HSPA and LTE software, which is integrated with Radisys’ layer 2, layer 3 and radio resource management components. The latest OCTBTS 3000 is suitable for building robust UMTS NodeB and LTE eNodeB solutions. Its small form factor, low power consumption and long range capability make it ideal for extended-coverage small cell solutions.

“We’re pleased to partner with Octasic to support the delivery of their OCTBTS platforms with our award-winning Trillium small cell software that has been deployed around the world,” said Todd Mersch, general manager, Software and Solutions, Radisys. “Our proven 3G and LTE small cell solutions deliver optimized performance and capabilities to deliver extended coverage and capacity that today’s overloaded networks require, while providing a path to multi-mode base stations.”

Small Cell Solutions at Mobile World Congress
Radisys is showcasing its small cell solutions at Mobile World Congress in Hall 5, Stand 5I61, February 24-27 in Barcelona. To see the OCTBTS 3000 at Mobile World Congress, please visit Octasic in booth 7G05, Hall 7.

About Radisys
Radisys (NASDAQ: RSYS) is a market leader enabling wireless infrastructure solutions for telecom, aerospace and defense applications. Radisys’ market-leading MRF (Media Resource Function) and T-Series Virtualized Platforms coupled with Trillium software, services and market expertise enable customers to bring their products to market faster with lower investment and risk. Radisys technology is used in a wide variety of 3G & 4G / LTE mobile network applications including: small cell Radio Access Networks (RAN), wireless core network applications, deep packet inspection (DPI) and policy management equipment; conferencing and media services including voice, video and data, as well as commercial offerings for network applications that support the aerospace and defense markets.

About Octasic
Octasic Inc. is a leading provider of SoCs, software, and integrated hardware/software platforms for the worldwide mobile wireless and media processing markets. Our hardware/software platforms are full-featured systems that allow developers to reduce costs, de-risk their projects, accelerate time to market, and focus engineering resources on their specific areas of expertise. The company’s high-quality solutions are based on Opus, a power-efficient asynchronous DSP architecture. Founded in 1998, Octasic is a private company headquartered in Montreal, Canada, with R&D facilities in India and a worldwide sales support network. For more information, please visit www.octasic.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

Octasic PR contact:
Charbel Dammous
Octasic Inc.
+1 514 282-8863
charbel.dammous@octasic.com

Wednesday, February 26th, 2014 Uncategorized Comments Off on (RSYS) and Octasic Partner to Deliver 3G and LTE Small Cell Solutions

(PEIX) to Restart Madera, California Plant

SACRAMENTO, Calif., Feb. 26, 2014  — Pacific Ethanol, Inc. (Nasdaq:PEIX), the leading marketer and producer of low-carbon renewable fuels in the Western United States, announced plans to restart production at its 40 million gallon per year facility in Madera, California, which would bring the company’s total operating production capacity to 200 million gallons per year. The company expects to begin ethanol production at Madera during the second quarter of 2014.

Neil Koehler, the company’s president and CEO, stated: “We are excited to achieve this important milestone for the company. With all of our plants in production we can further benefit from strong industry fundamentals and help meet the growing demand for low-carbon fuels in California. We are pleased to be providing new jobs and economic development in the Central Valley of California.”

About Pacific Ethanol, Inc.

Pacific Ethanol, Inc. (Nasdaq:PEIX) is the leading marketer and producer of low-carbon renewable fuels in the Western United States. Pacific Ethanol also sells co-products, including wet distillers grain (“WDG”), a nutritional animal feed. Serving integrated oil companies and gasoline marketers who blend ethanol into gasoline, Pacific Ethanol provides transportation, storage and delivery of ethanol through third-party service providers in the Western United States, primarily in California, Arizona, Nevada, Utah, Oregon, Colorado, Idaho and Washington. Pacific Ethanol has a 91% ownership interest in New PE Holdco LLC, the owner of four ethanol production facilities. Pacific Ethanol operates and manages the four ethanol production facilities, which have a combined annual production capacity of 200 million gallons. The facilities in operation are located in Boardman, Oregon, Burley, Idaho and Stockton, California, and one idled facility is located in Madera, California. The facilities are near their respective fuel and feed customers, offering significant timing, transportation cost and logistical advantages. Pacific Ethanol’s subsidiary, Kinergy Marketing LLC, markets ethanol from Pacific Ethanol’s managed plants and from other third-party production facilities, and another subsidiary, Pacific Ag. Products, LLC, markets WDG. For more information please visit www.pacificethanol.net.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

With the exception of historical information, the matters discussed in this press release including, without limitation, the ability of Pacific Ethanol to continue as the leading marketer and producer of low-carbon renewable fuels in the Western United States; the ability of Pacific Ethanol to timely restart production at its Madera, California plant, which will require, among other things, permit renewals, significant capital and successful testing and start-up activities; and the effects of restarting production at Pacific Ethanol’s Madera, California plant are forward-looking statements and considerations that involve a number of risks and uncertainties. The actual future results of Pacific Ethanol could differ from those statements. Factors that could cause or contribute to such differences include, but are not limited to, adverse economic and market conditions, including for ethanol and its co-products, and in particular, low-carbon rated ethanol; raw material costs; changes in governmental regulations and policies; and other events, factors and risks previously and from time to time disclosed in Pacific Ethanol’s filings with the Securities and Exchange Commission including, specifically, those factors set forth in the “Risk Factors” section contained in Pacific Ethanol’s Form 10-K filed with the Securities and Exchange Commission on April 1, 2013.

CONTACT: Company IR Contact:
         Pacific Ethanol, Inc.
         916-403-2755
         866-508-4969
         Investorrelations@pacificethanol.net

         IR Agency Contact:
         Becky Herrick
         LHA
         415-433-3777

         Media Contact:
         Paul Koehler
         Pacific Ethanol, Inc.
         916-403-2790
         paulk@pacificethanol.net
Wednesday, February 26th, 2014 Uncategorized Comments Off on (PEIX) to Restart Madera, California Plant

(PLUG) Milestone Order From Walmart for Multi-Site Hydrogen Fuel Cell Deployment

Deal Will Utilize Plug Power’s New GenKey Solution That Provides Fuel Cells, Hydrogen, Fuel Infrastructure and Maintenance Service

LATHAM, N.Y., Feb. 26, 2014  — Plug Power Inc. (Nasdaq:PLUG) today confirms the company has received a multi-site GenKey purchase order from Walmart Stores, Inc. to roll out its hydrogen fuel cell solution to power electric lift truck fleets at six North America distribution centers. The first of six sites will be deployed by the second quarter of 2014.

Further purchase order terms for the multi-site order initially announced on February 10, 2014 include:

  • Total of 1,738 GenDrive fuel cell units, to be deployed over two years
  • GenFuel infrastructure construction and hydrogen fuel supply
  • Six-year GenCare service contract for each site

GenDrive hydrogen fuel cells have universal appeal in material handling applications because they can contribute to an increase in productivity. Workers spend less time fueling a forklift truck as compared to changing a lead-acid battery, resulting in less downtime. GenDrive fuel cells also have no exhaust emissions so that they can be a component in implementing corporate environmental initiatives.

“We are pleased with the performance of the hydrogen fuel cells that we have been operating and are excited to expand our program with Plug Power,” said Jeff Smith, Senior Director for Walmart Logistics.

“This agreement is a tripling of Walmart’s commitment to Plug Power’s fuel cells, and is encouraging because it comes from a company with so much experience using our product,” said Andy Marsh, CEO at Plug Power. “This is a milestone for Plug Power and its ongoing business relationship with Walmart. Plug Power’s GenDrive products have a positive impact on the productivity of our customer’s operations. We have proven to be a trusted partner and are confident that GenKey will enhance Walmart’s material handling operations.”

Walmart currently has 535 GenDrive fuel cell units in operation at sustainable refrigerated distribution centers, including two sites in Canada and one in the United States. Specifically, Walmart’s Balzac, Canada, fresh food distribution center is the most energy-efficient distribution facility of its kind in North America. Additionally, the Walmart Washington Courthouse distribution center in Ohio was the launching point of the GenFuel business.

About Plug Power Inc.

The architects of modern fuel cell technology, Plug Power is revolutionizing the industry with cost-effective power solutions that increase productivity, lower operating costs and reduce carbon footprints. Long-standing relationships with industry leaders, including Walmart, Sysco, Procter & Gamble, and Mercedes Benz, forged the path for Plug Power’s innovative GenKey hydrogen and fuel cell system solutions. With more than 4,500 GenDrive units deployed to material handling customers, accumulating over 20 million hours of runtime, Plug Power manufactures tomorrow’s incumbent power solutions today. Additional information about Plug Power is available at www.plugpower.com.

Plug Power Inc. Safe Harbor Statement

This communication contains statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding our expectations regarding the timing and rollout of the new GenKey contract, the performance of our GenKey offering and the expansion into new markets. These forward-looking statements contain projections of our future results of operations or of our financial position or state other forward-looking information. We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. Investors are cautioned not to unduly rely on forward-looking statements because they involve risks and uncertainties, and actual results may differ materially from those discussed as a result of various factors, including, but not limited to: the risk that we continue to incur losses and might never achieve or maintain profitability, the risk that we may need to raise additional capital to fund our operations and such capital may not be available to us; the risk that we may not have enough cash to fund our operations to profitability and if we are unable to secure additional capital, we may need to reduce and/or cease our operations; the risk that a “going concern” opinion from our auditors, KPMG LLP, could impair our ability to finance its operations through the sale of equity, incurring debt, or other financing alternatives; our lack of extensive experience in manufacturing and marketing products may impact our ability to manufacture and market products on a profitable and large-scale commercial basis; the risk that unit orders will not ship, be installed and/or converted to revenue; the risk that pending orders may not convert to purchase orders; the risk that we fail to comply with NASDAQ’s listing standards which may result in our common stock being delisted from the NASDAQ stock market, which may severely limit our ability to raise additional capital; the cost and timing of developing, marketing and selling our products and our ability to raise the necessary capital to fund such costs; the ability to achieve the forecasted gross margin on the sale of our products; the risk that our actual net cash used for operating expenses exceeds our projected net cash for operating expenses; the cost and availability of fuel and fueling infrastructures for our products; market acceptance of our GenDrive systems; our ability to establish and maintain relationships with third parties with respect to product development, manufacturing, distribution and servicing and the supply of key product components; the cost and availability of components and parts for our products; our ability to develop commercially viable products; our ability to reduce product and manufacturing costs; our ability to successfully expand our product lines; our ability to improve system reliability for our GenDrive systems; competitive factors, such as price competition and competition from other traditional and alternative energy companies; our ability to protect our intellectual property; the cost of complying with current and future federal, state and international governmental regulations; and other risks and uncertainties discussed under “Item IA—Risk Factors” in Plug Power’s annual report on Form 10-K for the fiscal year ended December 31, 2012, filed with the Securities and Exchange Commission (“SEC”) on April 1, 2013 and as amended on April 30, 2013 and the reports Plug Power filed from time to time with the SEC. These forward-looking statements speak only as of the date on which the statements were made and are not guarantees of future performance. Except as may be required by applicable law, we do not undertake or intend to update any forward-looking statements after the date of this communication.

CONTACT: Plug Power Contact:
         Teal Vivacqua
         518.738.0269
         investor_relations@plugpower.com
Wednesday, February 26th, 2014 Uncategorized Comments Off on (PLUG) Milestone Order From Walmart for Multi-Site Hydrogen Fuel Cell Deployment

(EZCH) to Present at the Roth Capital Growth Stock Conference

YOKNEAM, Israel, February 26, 2014 —

EZchip Semiconductor Ltd. (NASDAQ: EZCH), a provider of network processors, today announced that its CEO, Mr. Eli Fruchter, will be presenting at the Annual Roth Capital Growth Stock Conference in Dana Point, California on March 10, 2014.

The Roth Capital Growth Stock Conference is taking place at the Ritz Carlton Hotel in Dana Point, California. EZchip is scheduled to present at 3:30pm Pacific Time on Monday, March 10, 2014.

At the Conference, there will be an opportunity for investors to meet one-on-one with Eli Fruchter, CEO of EZchip. Interested investors should contact the conference organizers at Roth, or the Investor Relations team at EZchip at ezchip@gkir.com.

About EZchip

EZchip is a fabless semiconductor company that provides Ethernet network processors for networking equipment. EZchip provides its customers with solutions that scale from 1-Gigabit to 100-Gigabits per second with a common architecture and software across all products. EZchip’s network processors provide the flexibility and integration that enable triple-play data, voice and video services in systems that make up the new Carrier Ethernet networks. Flexibility and integration make EZchip’s solutions ideal for building systems for a wide range of applications in telecom networks, enterprise backbones and data centers. For more information on our company, visit the web site at http://www.ezchip.com.

Contact:
Ehud Helft / Kenny Green
GK Investor & Public Relations
ezchip@gkir.com
Tel: (US)1-646-797-2868 / 1-646-201-9246

Wednesday, February 26th, 2014 Uncategorized Comments Off on (EZCH) to Present at the Roth Capital Growth Stock Conference

(CNET) Nominated as 2013 Preferred Service Provider for China SME

BEIJING, Feb. 26, 2014  — ChinaNet Online Holdings, Inc. (Nasdaq:CNET) (the “ChinaNet” or “Company”), a leading B2B (business to business) Internet technology company focusing on providing online-to-offline (“O2O”) sales channel expansion services for small and medium-sized enterprises (“SMEs”) and entrepreneurial management and networking services for entrepreneurs in the People’s Republic of China, today announced that it has been co-nominated as a candidate for the “2013 Preferred Service Provider for China Small and Medium-sized Enterprises” award by China Center for Promotion of SME Development and China International Cooperation Association of Small and Medium Enterprises.

“We are proud to be selected as one of the premier service provider to SMEs,” said Mr. George Chu, Chief Operating Officer of ChinaNet. “It validates our work in creating an excellent sales and marketing platform for SMEs. We will continue to introduce new products on our service platform to help franchise owners and SMEs become more successful.”

China Center for Promotion of SME Development is a state-owned entity under the Ministry of Industry and Information Technology of the People’s Republic of China to promote business development of domestic SMEs. China International Cooperation Association of Small and Medium Enterprises is a non-profit making entity established by various SMEs, entrepreneurs and scholars in 1990 to coordinate government-SMEs relationship and enhance oversea communications and activities of China SMEs.

About ChinaNet Online Holdings, Inc.

The Company, a parent company of ChinaNet Online Media Group Ltd., incorporated in the BVI (“ChinaNet”), is a leading B2B (business to business) Internet technology company focusing on providing O2O (online to offline) sales channel expansion service for small and medium-sized enterprises (SMEs) and entrepreneurial management and networking service for entrepreneurs in China. The Company, through certain contractual arrangements with operating companies in the PRC, provides Internet advertising and other services for Chinese SMEs via its portal websites, 28.com, Liansuo.com and Chuangye.com, TV commercials and program production via China-Net TV, and in-house LCD advertising on banking kiosks targeting Chinese banking patrons. Website: http://www.chinanet-online.com.

Safe Harbor

This release contains certain “forward-looking statements” relating to the business of ChinaNet Online Holdings, Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “estimates” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including business uncertainties relating to government regulation of our industry, market demand, reliance on key personnel, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. These forward-looking statements are based on ChinaNet’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting ChinaNet will be those anticipated by ChinaNet. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. ChinaNet undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONTACT: MZ North America
         Ted Haberfield, President
         Tel: +1-760-755-2716
         Email: thaberfield@mzgroup.us
         Web: www.mzgroup.us
Wednesday, February 26th, 2014 Uncategorized Comments Off on (CNET) Nominated as 2013 Preferred Service Provider for China SME

(LTRX) Demonstrates Solution to Connect Internet of Things Applications to Google Analytics

PremierWave(R) and xSenso(R) Product Lines Will Deliver Robust, Real-Time Reporting and Analytics

IRVINE, CA–(Feb 25, 2014) –  Lantronix, Inc. (NASDAQ: LTRX), a leading global provider of smart IoT (Internet of Things) connectivity solutions, today announced it has demonstrated firmware that will make several Lantronix® products easily configurable to enable delivery of meaningful data to the Google Analytics™ web analytics service. Google Analytics — the world’s leading web analytics software, in use by more than 10 million websites alone — provides a full suite of customizable analytics, modeling, and reporting features. Lantronix is planning to incorporate this new functionality into its PremierWave® and xSenso® product families. The company provided a live demonstration of its Google Analytics-connected solutions at the Embedded World 2014 show this week in Nürnberg, Germany.

“The promise of M2M and the Internet of Things lies not in the technical specifications of the products themselves, but in how these products provide solutions that make life better — for consumers and businesses alike,” said Kurt Busch, president and chief executive officer for Lantronix. “Incorporating Google Analytics into our product offerings yields a simple, easy to use analytics engine for almost any machine. The ability to access real-time data, customized to meet the user’s needs, to whatever device, wherever it’s located, is what will drive the next wave of M2M adoption.”

The first product families expected to include Google Analytics functionality include:

PremierWave

  • PremierWave® XC-HSPA+: Industrial grade 3.5G cellular solution offering Penta-band HSPA+ performance, network redundancy, and enterprise-level security for mission critical applications, time sensitive event tracking, and M2M connectivity.
  • PremierWave® XC (2G): High performance, multi-port secure device server that offers Ethernet or GSM/GPRS cellular connectivity for remote access and easy management of machines and equipment over the network and across the Internet.
  • PremierWave® XN: Multi-port application server that offers high performance Ethernet or Wi-Fi connectivity for remote access and easy management of machines or equipment over the network and across the Internet.
  • PremierWave® EN: High performance Industrial ready ARM 9 system on module (SOM) suitable for Wi-Fi M2M applications. It is offered as a small removable module with integrated Flash and RAM and dual band 802.11 a/b/g/n capabilities. The PremierWave EN is an ideal solution for embedded applications that require simple development, ease of use and a proven robust high performing solution with network connectivity.

xSenso
The Lantronix xSenso product family comprises feature-rich, low cost solutions for remote sensor monitoring and process control.

  • xSenso®: Compact DIN-rail or wall mount solution that enables analog sensors (voltage or current) to easily and transparently send real-time data to any node on the Internet or to a cloud based application. The options of two analog outputs (voltage or current) or two mechanical relays (AC or DC) make the xSenso a complete industrial process controller.
  • xSenso® Controller: The Controller version of the xSenso analog sensor networking family is designed specifically for use in rugged and harsh environments including industrial automation, process control, manufacturing, chemicals, oil and gas industries, and many more. The new analog and relay outputs provide the ability to take action by instantly controlling industrial processes and equipment based on the sensor readings and predefined thresholds to solve real-time problems.

How to Buy
Lantronix PremierWave® and xSenso® family products are available for purchase directly at www.Lantronix.com, by calling (800) 422-7055, or through the Company’s global network of distribution channels and reseller partners. For more information or general questions about xSenso products, please contact us at sales@lantronix.com.

About Lantronix
Lantronix, Inc. (NASDAQ: LTRX) is a global leader of secure communication technologies that simplify access and communication with and between virtually any electronic device. Our smart M2M (machine-to-machine) and IoT (Internet of Things) connectivity solutions enable sharing data between devices and applications to empower businesses to make better decisions based on real-time information, and gain a competitive advantage by generating new revenue streams, improving productivity and increasing efficiency and profitability. Easy to integrate and deploy, Lantronix products remotely and securely connect electronic equipment via networks and the Internet. Founded in 1989, Lantronix products have applications in every industry, including medical, security, industrial and building automation, transportation, retail, POS, financial, government, consumer electronics, and IT/data center. The Company’s headquarters are located in Irvine, California. For more information, visit www.lantronix.com. The Lantronix blog, http://www.lantronix.com/blog, features industry discussion and updates. To follow Lantronix on Twitter, please visit http://www.twitter.com/Lantronix.

© 2014 Lantronix, Inc. All rights reserved. Lantronix, PremierWave, and xSenso are registered trademarks of Lantronix, Inc. Google Analytics is a trademark of Google Inc. All other trademarks and trade names are the property of their respective holders. Specifications subject to change without notice.

Media Contacts:
Stephanie Olsen
Lages & Associates, Inc.
stephanie@lages.com
949.453.8080

Rosie Anderson
TOUCHDOWNPR
randerson@touchdownpr.com
+44 1252 717040

Investor Contact:
E.E. Wang
investors@lantronix.com
949-614-5879

Lantronix Contact:
Mark D. Tullio
Lantronix
mark.tullio@lantronix.com
949.453.7124

Tuesday, February 25th, 2014 Uncategorized Comments Off on (LTRX) Demonstrates Solution to Connect Internet of Things Applications to Google Analytics

(GNCA) to Present at the Cowen and Company 34th Annual Health Care Conference

Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell enabled vaccines and immunotherapies, announced today that its president and chief executive officer, Chip Clark, will present a company overview at the Cowen and Company 34th Annual Health Care Conference. The presentation is scheduled for Monday, March 3, 2014 at 4:10 p.m. EST at the Boston Marriott Copley Place.

A live webcast of the presentation can be accessed by visiting the investor relations section of the Genocea website at www.ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.

About Genocea Biosciences, Inc.

Genocea is harnessing the power of T cell immunity to develop the next generation of vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but are difficult to target using traditional discovery methods. Genocea is able to identify protective T cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform, potentially enabling vaccines against pathogens for which vaccine solutions do not exist or are sub-optimal. Genocea’s pipeline of novel clinical stage T cell enabled vaccines includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria. For more information, please visit the company’s website at www.genocea.com.

Tuesday, February 25th, 2014 Uncategorized Comments Off on (GNCA) to Present at the Cowen and Company 34th Annual Health Care Conference